Evidence map›Paper›PMID 19657747›Full record

ReviewNeuromolecular medicine2009

Manganese and its role in Parkinson's disease: from transport to neuropathology.

Michael Aschner, Keith M Erikson, Elena Herrero Hernández, Elena Herrero Hernández, Ronald Tjalkens

Erratum issuedOpen access · greenAbstract readReview
In one paragraph

Review in Neuromolecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 148 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 1 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 1 synthesis or guideline pooled it, 300 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. MnAntioxidants (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Common and Trace Metals in Alzheimer's and Parkinson's Diseases.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Development of MnInternational journal of molecular sciences · 2023
    Article

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Hernández, Elena Herrero [corrected to Herrero Hernández, Elena]
5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Michael AschnerDepartments of Pediatrics and Pharmacology and the Kennedy Center for Research on Human Development, Vanderbilt University Medical Center, 2215-B Garland Avenue, 11425 MRB IV, Nashville, TN, 37232-0414, USA. michael.aschner@vanderbilt.edu
Keith M Erikson
Elena Herrero Hernández
Elena Herrero Hernández
Ronald Tjalkens
Colorado State University · USOregon Health & Science University · USUniversity of North Carolina at Greensboro · USVanderbilt University Medical Center · US

Funding

Manganese and basal ganglia dysfunction: role of NOR01ES012941 · NIEHS · COLORADO STATE UNIVERSITY-FORT COLLINS · PI TJALKENS, RONALD · 2005 to 2010
$1.4M
Manganese & Basal Ganglia Dysfunction: Role of NOR56ES012941 · NIEHS · COLORADO STATE UNIVERSITY · PI TJALKENS, RONALD · 2010 to 2010
$106k
NIEHS NIH HHS R01 ES012941NIEHS NIH HHS R56 ES012941PHS HHS NIEHS 012941PHS HHS NIEHS 10563PHS HHS NINDS 061309-01
6 · The paper itself

Abstract

The purpose of this review is to highlight recent advances in the neuropathology associated with Mn exposures. We commence with a discussion on occupational manganism and clinical aspects of the disorder. This is followed by novel considerations on Mn transport (see also chapter by Yokel, this volume), advancing new hypotheses on the involvement of several transporters in Mn entry into the brain. This is followed by a brief description of the effects of Mn on neurotransmitter systems that are putative modulators of dopamine (DA) biology (the primary target of Mn neurotoxicity), as well as its effects on mitochondrial dysfunction and disruption of cellular energy metabolism. Next, we discuss inflammatory activation of glia in neuronal injury and how disruption of synaptic transmission and glial-neuronal communication may serve as underlying mechanisms of Mn-induced neurodegeneration commensurate with the cross-talk between glia and neurons. We conclude with a discussion on therapeutic aspects of Mn exposure. Emphasis is directed at treatment modalities and the utility of chelators in attenuating the neurodegenerative sequelae of exposure to Mn. For additional reading on several topics inherent to this review as well as others, the reader may wish to consult Aschner and Dorman (Toxicological Review 25:147-154, 2007) and Bowman et al. (Metals and neurodegeneration, 2009).

Indexed as

Occupational ExposureAnimalsBiological TransportChelating AgentsChelation TherapyEnergy MetabolismHumansManganeseManganese PoisoningMembrane Transport ProteinsMiceMitochondriaNeurogliaParkinson Disease, SecondaryRatsSynaptic TransmissionChelating AgentsManganeseMembrane Transport Proteins

Identifiers

PMID19657747
PMCPMC4613768
OpenAlexW2070782607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.